drugset / Trial / NCT01801280

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

NCT01801280

Phase 4 Completed 20 enrolled Klemens Budde Novartis Pharmaceuticals · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this pharmacokinetic study is to examine a possible drug-drug interaction of Pantoprazole on the bioavailability mycophenolic acid.

Timeline

Start
2012-01
Primary completion
2013-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 1000 mg
Subject Mycophenolate Mofetil Small molecule 1500 mg
Subject Mycophenolate Mofetil Small molecule 2000 mg
Subject Mycophenolate Sodium Unknown 720 mg
Subject Mycophenolate Sodium Unknown 1080 mg
Subject Mycophenolate Sodium Unknown 1440 mg
Subject Pantoprazole Other / unclassified 40 mg